CybeRelease: (OTC: MNCL) Has Translated the Medical Crisis Book in French to Capitalize on the Estimated Half a Billion Dollar Quebec Market
(CybeRelease, March 29, 2007) – Lake Harmony, Pa. - Martin Nutraceuticals Inc. (OTC PK: MNCL) is pleased to announce that it has completed the translation of Dr. Martin’s New book - Medical Crisis, Secrets Your Doctor Won’t Share With You, into the French Language. According to Statistics Canada, Canadian book sales exceeded over 2 billion dollars annually in the recent years and the Province of Quebec represented over 22% of those sales.
“It seemed like the logical thing to do. We are listed with major retail stores, health stores and pharmacies throughout Quebec so why not try to piggy back our book with current retailers that already carry our flagship products,” stated Harvey Panesar, President of Martin Nutraceuticals Inc. “Our business model remains consistent in that we will use the DRTV (infomercial) medium for US market penetration and the retail medium through Dr. Martin’s brand recognition in Canada. We had earlier announced that we had a purchase order from Chapter/Indigo, the largest book retailer in Canada and we are now hoping with our book being available in French we can make inroads with new book retailers that would not have been other wise available to us.”
Martin Nutraceuticals new website for the Medical Crisis book, www.medicalcrisisthebook.com will be unveiled shortly and will include the new French copy.
For more information, please contact Investor Relations at (973) 351-3868 or http://www.martinnutra.com/
About Martin Nutraceuticals Inc.
Martin Nutraceuticals Inc. is a company focused on providing a better health and lifestyle through natural products. Martin Nutraceuticals flagship products include Arthrizyme(TM) for general joint pain and Oxygenol(TM) for anti-oxidation and Maximum Slim(TM) for weight control.
Arthrizyme(TM) is a unique blend of systemic enzymes proven to rapidly reduce inflammation in joints and muscles. Arthrizyme(TM) is not limited to anti-inflammatory effects; it also assists the body in the healing process by breaking down fibrin in joints and muscles. Arthrizyme(TM) differs from all other natural arthritis remedies and was designed to work for all types of arthritis and in all joints of the body. Arthrizyme(TM) is fast acting, usually improving symptoms within the first few days.
To read the complete release, go to http://biz.yahoo.com/bw/070329/20070329005139.html?.v=1
For a Free Newsletter, go to http://www.OTCReporter.com
CybeRelease Gainers are PDL BioPharma, Inc. (Nasdaq: PDLI), Hansen Natural Corporation (Nasdaq: HANS), Thoratec Corporation (Nasdaq: THOR), SunPower Corporation (Nasdaq: SPWR), Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), CEPHEID (Nasdaq: CPHD), F5 Networks, Inc. (Nasdaq: FFIV) and Tetra Tech, Inc. (Nasdaq: TTEK).
CybeRelease Decliners are Adobe Systems Incorporated (Nasdaq: ADBE), Network Appliance, Inc. (Nasdaq: NTAP), Research in Motion Limited (Nasdaq: RIMM), Akamai Technologies, Inc. (Nasdaq: AKAM), Polycom, Inc. (Nasdaq: PLCM), Fifth Third Bancorp (Nasdaq: FITB), Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Infosys Technologies Limited (Nasdaq: INFY).
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid CybeRelease $500.00 for the publication of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation and do no trading of any kind.
- Contact Information
- C. P. Barry
- Media Contact
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.